Daxor Corporation (DXR)
NASDAQ: DXR · IEX Real-Time Price · USD
9.75
+0.15 (1.56%)
Apr 19, 2024, 3:16 PM EDT - Market closed
Company Description
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing.
The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.
The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973.
Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
Daxor Corporation
| Country | United States |
| Founded | 1970 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Michael Richard Feldschuh |
Contact Details
Address: 350 Fifth Avenue, Suite 4740 New York, New York 10118 United States | |
| Phone | 212-330-8500 |
| Website | daxor.com |
Stock Details
| Ticker Symbol | DXR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000027367 |
| CUSIP Number | 239467103 |
| ISIN Number | US2394671034 |
| Employer ID | 13-2682108 |
Key Executives
| Name | Position |
|---|---|
| Michael Richard Feldschuh | Chairman, President and Chief Executive Officer |
| Jonathan Adam Feldschuh | Chief Scientific Officer and Director |
| Robert J. Michel CPA, CPA, M.B.A. | Chief Financial Officer, Chief Compliance Officer and Corporate Secretary |
| Linda Cooper | Vice President of Development and Operations |
| Kathryn A. Kornafel | Senior Vice President of Marketing and Commercial Development |
| Guido Manzo | Vice President of Sales |
| Jean Oertel | Senior Vice President Commercialization and Customer Experience |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 3, 2024 | 40-17F2 | Filing |
| Apr 3, 2024 | 40-17F2 | Filing |
| Apr 3, 2024 | 40-17F2 | Filing |
| Mar 25, 2024 | 8-K | Current Report |
| Mar 19, 2024 | N-CSR/A | Filing |
| Mar 15, 2024 | N-CEN | Filing |
| Mar 15, 2024 | N-CSR | Filing |
| Mar 8, 2024 | NT-NCSR/A | Filing |
| Feb 29, 2024 | NT-NCSR/A | Filing |
| Feb 29, 2024 | NT-NCSR | Filing |